Mode
Text Size
Log in / Sign up
Phase 3 N=971 Randomized Double-blind Treatment

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

Enrolled (actual)
971
Serious AEs
3.2%
Results posted
Jan 2020
Primary outcome: Primary: Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6 — 64.03; 62.19; 64.97; -16.57 minutes — p=<.0001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
lemborexant (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Eisai Inc.
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6
64.03; 62.19; 64.97; -16.57; -29.39; -32.49 <.0001 sig
SECONDARY
Change From Baseline in sSOL at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1 and 3
64.03; 62.19; 64.97; -4.11; -16.86; -18.89 <.0001 sig
SECONDARY
Change From Baseline in Subjective Sleep Efficiency (sSE) at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6
61.34; 63.14; 62.03; 2.68; 6.61; 8.27 <.0001 sig
SECONDARY
Change From Baseline in Subjective Wake After Sleep Onset (sWASO) at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6
132.49; 132.77; 136.83; -6.12; -20.21; -23.30 <.0001 sig
SECONDARY
Change From Baseline in sTST at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6
304.25; 315.52; 306.89; 14.78; 34.29; 46.01 <.0001 sig
SECONDARY
Percentage of Sleep Onset Responders and Sleep Maintenance Responders at Month 6
17.7; 31.2; 30.1; 20.4; 35.0; 30.0 0.0004 sig
SECONDARY
Percentage of Sleep Onset Responders and Sleep Maintenance Responders at Month 12
34.2; 37.2; 35.0; 39.6
SECONDARY
Change From Baseline in Insomnia Severity Index (ISI) Daytime Functioning Score at Months 1, 3, and 6
11.0; 11.4; 11.0; -3.1; -4.1; -4.2 0.0137 sig
SECONDARY
Change From Baseline in Fatigue Severity Scale (FSS) Total Score at Months 1, 3 and 6
35.2; 37.4; 36.0; -3.9; -6.6; -6.4 0.0670
SECONDARY
Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Placebo-Controlled Period), and at Months 1, 3 and 6
3.94; 3.93; 3.93; 0.15; 0.36; 0.33 0.0067 sig
SECONDARY
Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the Beginning of Treatment (Mean of the 7 Nights After the First Dose in Active Treatment Period)
4.15; 4.16; 0.36; 0.33
SECONDARY
Change From Screening in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at the First and Second 7 Mornings of the Follow-up Period
3.63; 3.54; 1.03; 1.32; 0.98; 1.22
SECONDARY
Change From Baseline in Mean Rating on the Morning Sleepiness Item of the Sleep Diary at Months 1, 3, 6, 9 and 12
4.15; 4.16; 0.46; 0.42; 0.60; 0.70
SECONDARY
Rebound Insomnia: Mean sSOL on Each of the First 3 Nights, First 7 Nights, and Last 7 Nights of the Follow-up Period
40.35; 41.73; 41.35; 41.90; 44.10; 41.30
SECONDARY
Rebound Insomnia: Mean sWASO on Each of the First 3 Nights, First 7 Nights, and Last 7 Nights of the Follow-up Period
86.66; 97.88; 91.56; 95.79; 92.62; 98.19
SECONDARY
Rebound Insomnia: Percentage of Participants Whose sSOL Was Longer Than at Screening for First 3 Nights of the Follow-up Period, or Whom Mean sSOL Was Longer Than at Screening for First 7 Nights or Last 7 Nights of the Follow-up Period
9.46; 9.38; 11.94; 10.53; 11.71; 9.38
SECONDARY
Rebound Insomnia: Percentage of Participants Whose sWASO is Higher Than at Screening for First 3 Nights of the Follow-up Period, or Whose Mean sWASO is Higher Than at Screening for the First 7 Nights or Last 7 Nights of the Follow-up Period
11.26; 12.59; 12.39; 14.19; 13.51; 11.90
SECONDARY
Persistence of Effect: Mean Change From Baseline in sSOL, sWASO, and sTST at Months 3, 6, 9, and 12 Compared to Month 1
-17.17; -18.64; -21.47; -21.58; -24.13; -22.99
SECONDARY
Persistence of Effect: Mean Change From Baseline in sSE at Months 3, 6, 9, and 12 Compared to Month 1
6.35; 7.32; 10.01; 10.25; 11.10; 11.08
SECONDARY
Persistence of Effect: Mean Change From Period 2 Baseline (Month 6) in sSOL, sWASO, and sTST at Months 9 and 12 Compared to Month 7
-28.55; -29.46; -32.10; -30.91; -31.40; -31.33
SECONDARY
Persistence of Effect: Mean Change From Period 2 Baseline (Month 6) in sSE at Months 9 and 12 Compared to Month 7
12.88; 15.12; 16.54; 16.49; 16.34; 16.82
SECONDARY
Persistence of Effect: Mean Change From Study Baseline and Period 2 Baseline (Month 6) in sSOL, sWASO, and sTST at Months 3 and 6 Exposure Compared to Month 1
-17.17; -18.64; -21.47; -21.58; -24.13; -22.99
SECONDARY
Persistence of Effect: Mean Change From Study Baseline and Period 2 Baseline (Month 6) in sSE at Months 3 and 6 Exposure Compared to Month 1
6.35; 7.32; 10.01; 10.25; 11.10; 11.08

Summary

The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.

Eligibility Criteria

Inclusion Criteria

  • Male or female, age 18 years or older at the time of informed consent
  • Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder, as follows:
  • Complains of dissatisfaction with nighttime sleep in the form of difficulty getting to sleep, difficulty staying asleep, and/or awakening earlier in the morning than desired despite adequate opportunity for sleep
  • Frequency of complaint ≥3 times per week
  • Duration of complaint ≥3 months
  • Associated with complaint of daytime impairment
  • History of (Subjective Sleep Onset Latency) sSOL ≥30 minutes on at least 3 nights per week in the previous 4 weeks and/or subjective Wake after Sleep Onset (sWASO) ≥60 minutes on at least 3 nights per week in the previous 4 weeks
  • History of regular time spent in bed, either sleeping or trying to sleep, between 7 and 9 hours
  • Regular bedtime, between 21:00 and 01:00 and regular wake time, the time the participant gets out of bed for the day, between 05:00 and 10:00
  • Insomnia Severity Index (ISI) score ≥15
  • Confirmation of current insomnia symptoms as determined from the Sleep Diary completed on at least 7 consecutive mornings (minimum 5 of 7 for eligibility), such that sSOL ≥30 minutes on at least 3 of the 7 nights and/or sWASO ≥60 minutes on at least 3 of the 7 nights
  • Confirmation of time spent in bed, as determined from on the Sleep Diary completed on 7 mornings between the first and second screening visit, such that there are not more than 2 nights with duration of time spent in bed 7 hours and 10 hours
  • Confirmation of regular bedtimes and wake times such that the participant has a regular time spent in bed, either sleeping or trying to sleep, between 7 and 10 hours for the final 7 nights of the before visit 3.
  • Confirmation of regular bedtime between 21: 00 and 01:00 and time of getting out of bed for the day between 05:00 and 10:00 for the final 7 nights of the before visit 3.
  • Willing and able to comply with all aspects of the protocol, including staying in bed for at least 7 hours each night
  • Willing to not start a behavioral or other treatment program for insomnia during the participants participation in the study

Exclusion Criteria

  • A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, or an exclusionary score on screening instruments to rule out individuals with symptoms of certain sleep disorders other than insomnia.
  • STOPBang score greater than or equal to (>=) 5
  • International Restless Legs Scale (IRLS) score >=16
  • Epworth Sleepiness Scale (ESS) score >15
  • Reports symptoms potentially related to narcolepsy that in the clinical opinion of the investigator indicates the need for referral for a diagnostic evaluation for the presence of narcolepsy
  • Reports a history of sleep-related violent behavior, or sleep driving, or any other complex sleep-related behavior, eg, making phone calls, or preparing and eating food while asleep
  • For participants who underwent polysomnography (PSG) within the previous year:
  • Age 18 to 64 years: Apnea Hypopnea Index ≥10, or Periodic Limb Movements with Arousal Index ≥10
  • Age ≥65 years: Apnea Hypopnea Index >15, or Periodic Limb Movements with Arousal Index >15
  • Beck Depression Inventory - II (BDI II) score >19 at Screening
  • Beck Anxiety Inventory (BAI) score >15 at Screening
  • Habitually naps more than 3 times per week
  • Females who are breastfeeding or pregnant at Screening or Study Baseline
  • Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.)
  • Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02952820). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search